IPTA December 2017 Newsletter

ipta newsletter

Holiday Greetings | Donate to IPTA Now! | Announcement: IPTA 2018 Symposium in Organ Transplantation in Children | Ethical Case Request | Announcement of New Editors | Writing Project Proposal Form | IPTA ID Committee Update | PJP surveyRecent publications of interest in the arena of antibody mediated rejection | IPTA Reduced Dues for 2018!

Holiday Greetings


On behalf of the leadership of the International Pediatric Transplant Association, may you have a peaceful, joyful holiday season. Thank you for dedicating this past year to your patients and families, and thank you for your tireless efforts to advocate for all children who need transplantation. We look forward to serving you in 2018.

ad signature

Anne Dipchand
President of IPTA

Donate to IPTA Now!


Donate to IPTA Now! Your donation will be used to help IPTA to promote the advancement of the science and practice of transplantation in children worldwide and to serve as a unified voice for the special needs of pediatric transplant recipients.


Announcement: IPTA 2018 Symposium in Organ Transplantation in Children

The International Pediatric Transplant Association is proud to feature a special section activity: the 2018 Symposium in Organ Transplantation in Children: An educational forum for physicians, surgeons, and allied health professionals.

The focus of this symposium is aimed at clinical and research fellows in pediatric solid organ transplantation, as well as residents, and other allied health professional or non-physician trainees who are planning a career in pediatric transplantation.

The symposium will also provide state of the art information to established physicians, surgeons and allied health professionals who participate in the care of children before or after solid organ transplantation. In this case, a registration fee of $150/ person applies. Maximum capacity for established practitioners will be 50.


Pneumocystis jiroveci (PJP) survey

PJP survey

Pneumocystis jiroveci (PJP) remains an import pathogen among organ transplant recipients. While there are published guidelines for PJP prophylaxis following transplantation, in practice, there is likely wide variability in the individual approach to prophylaxis. To better clarify the current practice among transplant centers, we are conducting a survey to assess the use of PJP prophylaxis following pediatric solid organ transplant recipients. The link to the survey is included in this edition of the Newsletter. It is approximately 12 questions and should take fewer than 10 minutes to complete.

We appreciate you taking the time to COMPLETE THE SURVEY, and all responses will remain anonymous.

Ethical Case Request

Do you have cases that keep you up at night? Please share them with us!

Organ transplantation, particularly in children, is a process fraught with ethical questions. We routinely make decisions that can greatly impact our patients' lives with far from perfect information. How poor a prognosis does a patient have to have before he or she is no longer a transplant candidate? How should we weigh non-medical factors when making decisions? What allocation systems should we advocate for or emulate?


Announcement of New Editors

IPTA is pleased to announce the appointment of two new editors for its journal, Pediatric Transplantation: Drs. Burkhard Tönshoff and Sharon Bartosh.


IPTA is pleased to announce the appointment of two new editors for its journal, Pediatric Transplantation: Drs. Burkhard Tönshoff and Sharon Bartosh.



IPTA is pleased to announce the appointment of two new editors for its journal, Pediatric Transplantation: Drs. Burkhard Tönshoff and Sharon Bartosh.

IPTA is very grateful to Dr. Steven Webber for all of his service to IPTA. He was a founding Council member of IPTA, served as its third President, and for the last 5 years has served as Editor-in-Chief of Pediatric Transplantation.


Proposals for ipta-sponsored Writing Projects

The International Pediatric Transplant Association is dedicated to advancing the science and practice of pediatric transplantation worldwide, in order to improve the health of all children who require such treatment. To achieve this, part of our mission is to generate and disseminate information in the field of pediatric transplantation to our members and to the transplant community worldwide. This is primarily accomplished through the publication of important original research, review articles, commentaries and summaries to our journal, Pediatric Transplantation.


IPTA Infectious Diseases Committee Update

ID Committee

The IPTA Infectious Diseases (ID) Committee continues to be actively involved in generating information and guidance to benefit our members and the children that we care for. In many cases, members of the committee are collaborating with other members of IPTA to carry out these projects and develop manuscript and guidance. Amongst our current initiatives, the Committee is working with members of IPTA who participated in the 3rd TTS Consensus Conference on CMV this last spring to provide a pediatric perspective on the soon to be published updated CMV Guidelines. It is anticipated that this will follow a “Question and Answer” format and will be published in Pediatric Transplantation in 2018.


Recent publications of interest in the arena of antibody mediated rejection

  •  Jordan, SC et al.  IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation.  N Engl J Med. 377: 5: 2017

    This is a report of 25 highly sensitized patients transplanted in 2 countries (Sweden, USA), with IdeS in an open label phase 1-2 trial of desensitization and transplant.   IdeS, a cysteine protease, is an IgG-degrading enzyme derived from Step pyogenes.  It is an endopeptidase that cleaves human IgG into F(ab’)2 and Fc fragments inhibiting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.  Immunosuppression protocols differed significantly between the 2 countries.  IdeS was shown to reduce or eliminate donor-specific antibodies and permitted HLA-incompatible transplantation in 24 of the 25 patients.  There was a single allograft loss due to hyperacute rejection and 5 patients developed antibody mediated rejection.  
  • Choi J., et al.    Assessment of Tocilizumab (Anti-Interleuken-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant glomerulopathy in HLA-Sensitized Renal Allograft Recipients.  AJT. 17. 2017

    This is a single center, open label report of 36 renal transplant patient with cAMR plus DSAs and transplant glomerulopathy who were treated as rescue therapy (progressive dysfunction having failed treatment with IVIg plus rituximab with or without PLEX), with monthly infusions of the anti-IL-6 receptor monoclonal antibody tocilizumab.  Tocilizumab binds to both soluble and membrane-bound forms of the IL-6R and is approved by the FDA for treatment of rheumatoid arthritis and juvenile idiopathic arthritis.  Significant reductions in DSAs and stabilization of renal function were seen at 2 years.   Confirmation of this uncontrolled report, of course is necessary. 
  • Clayton PA, Coates P.  Are Sensitized Patients Better off with a Desensitization transplant or waiting on dialysis?   Kidney International. 91. 2017

    Although this article refers to 2 manuscripts (N Eng J Med: 374: 940-959. 2016 and Lancet; 389:727-734. 2017) which report conflicting results regarding the survival benefit of transplantation in sensitized adult kidney transplant patients, the questions addressed are not different for children.  Wait for a well matched kidney or desensitize and attempt transplant??

IPTA Reduced Dues for 2018!




MEMBER LEVEL 1 Year (USD) 2 Years (USD)
Physicians $225 $200 (USD) $400 $380 (USD)
Trainees $115 $75 (USD) $210 $140 (USD)
Allied Health $115 $100 (USD) $210 $190 (USD)
Emerging Economy 55 (USD) 100 (USD)